Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

SA Transcripts 162.1K Followers Follow Kazia Therapeutics Limited ( KZIA ) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer September 1, 2026 8:00 AM EDT Company Participants John Friend - Chief Executive Officer Sudha Rao - Chief Scientific Officer Conference Call Participants Kambiz Yazdi - BTIG, LLC, Research Division Chad Messer - Lake Street Capital Markets, LLC, Research Division John Newman - Canaccord Genuity Corp., Research Division Presentation Operator Good morning, and welcome to Kazia Therapeutics Corporate Update Call. [Operator Instructions] Please note that today's call is being recorded. Before we begin, I would like to direct your attention to the forward-looking statements disclaimer displayed on the screen. We encourage you to review this information, which applies to the statements made during today's presentation. I would now like to turn the call over to Dr. John Friend, Chief Executive Officer. John Friend Chief Executive Officer All right. Good morning, everybody, and thank you for joining us today. On behalf of Kazia Therapeutics, I appreciate your time to participate in today's investor call. I'm joined today by our Chief Scientific Officer, Professor Sudha Rao. Together, we'll provide a corporate and clinical update following several recent announcements across the paxalisib program, including our emerging data in triple-negative breast cancer, our planned expansion into HR+/HER2- breast cancer and our colorectal cancer program. More importantly, we want to use today's call to connect these developments and provide some perspective on what we believe are emerging clinical and translational data and telling us about pax and how it is shaping our development strategy going forward. With that, let's get started. So today, we're going to provide an update about paxalisib and investment framework. Then we're going to go into the new data with regard to triple-negative breast, our program in HR+, early-stage triple-negative breast, but also pMMR colorectal cancer. We're going to talk a